8-KItem 8.01 · Other EventsItem 9.01 · Financial Statements
AbbVie Inc. (ABBV)

AbbVie ($ABBV) filed Form 8‑K (Item 9.01) attaching an Underwriting Agreement dated Feb 24, 2026 among…

Filed with the SEC on · Summarized by InvestorsBot

AbbVie ($ABBV) filed Form 8‑K (Item 9.01) attaching an Underwriting Agreement dated Feb 24, 2026 among AbbVie and J.P. Morgan, BofA Securities, Morgan Stanley & Wells Fargo (acting as reps/underwriters). 📝 #SECfiling #CorporateFinance

Exhibits: 1.1 (Underwriting Agreement) and 104 (Inline XBRL cover page). Filing contains standard PSLRA forward‑looking disclosures. Report signed Feb 26, 2026 by CFO Scott T. Reents. 📄 $ABBV #InvestorAlert #SECfiling

The 8‑K does NOT disclose offering size, security type or price—only the underwriting agreement. Investors should watch for a prospectus/supplement for deal terms. ℹ️ $ABBV #Offering #Investing

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from AbbVie Inc.

AbbVie 8-K (Item 9.01) — Supplemental Indenture No.

8-K · March 4, 2026

On Mar 4, 2026 AbbVie completed an $8.0B notes offering: $750M floating-rate due 2028; $1.5B 3.775% due…

8-K · March 4, 2026

AbbVie ($ABBV) 2/24/26 agreed to sell $8.0B of senior notes across seven tranches (2028–2066); pricing…

8-K · February 26, 2026

AbbVie files Form 8‑K dated Feb 4, 2026: furnishes press release (Exhibit 99.1) pursuant to Item 2.02;…

8-K · February 4, 2026

AbbVie ($ABBV) issued a press release on Feb 4, 2026 announcing Q4 & FY 2025 financial results.

8-K · February 4, 2026

AbbVie filed an 8‑K on Jan 7, 2026.

8-K · January 7, 2026